Karyopharm Therapeutics
KPTI
$1.10
Share price
3.77%
Change (1 day)
-71.43%
Change (1 year)
Categories
Karyopharm Therapeutics (KPTI) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $0.37 B
According to Karyopharm Therapeutics 's latest financial reports the company's total liabilities are $0.37 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Karyopharm Therapeutics - Total liabilities on balance sheet (from 2012 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $0.37 B | 0.48% |
| 2022-12-31 | $0.37 B | -2.64% |
| 2021-12-31 | $0.38 B | 46.66% |
| 2020-12-31 | $0.26 B | 7.06% |
| 2019-12-31 | $0.24 B | 55.16% |
| 2018-12-31 | $0.15 B | 210.88% |
| 2017-12-31 | $50.83 M | 180.18% |
| 2016-12-31 | $18.14 M | 6.23% |
| 2015-12-31 | $17.07 M | 26.1% |
| 2014-12-31 | $13.54 M | 311.39% |
| 2013-12-31 | $3.29 M | -88.72% |
| 2012-12-31 | $29.18 M | 46.86% |
| 2011-12-31 | $19.87 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | $34.38 B | 9,029.84% | 🇺🇸 USA |
 Merck MRK | $69.04 B | 18,230.31% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $82.48 B | 21,799.46% | 🇺🇸 USA |
 Exelixis EXEL | $0.67 B | 80.13% | 🇺🇸 USA |